N4CN Stock Overview Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Paratek Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Paratek Pharmaceuticals Historical stock prices Current Share Price US$2.02 52 Week High US$3.65 52 Week Low US$1.19 Beta 1.7 1 Month Change 2.90% 3 Month Change n/a 1 Year Change -13.95% 3 Year Change -57.52% 5 Year Change -75.32% Change since IPO -86.37%
Recent News & Updates Paratek Pharmaceuticals, Inc. Announces Board Changes Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index
CEO & Director recently sold €98k worth of stock Aug 13
Insufficient new directors Aug 09
Forecast to breakeven in 2025 Aug 09
Paratek Pharmaceuticals, Inc. Announces Modification of Barda Contract to Advance the Development of Nuzyra®? (Omadacycline) for Post-Exposure Prophylaxis (Pep) and Treatment of Pulmonary Anthrax Jul 11 See more updates Paratek Pharmaceuticals, Inc. Announces Board Changes Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index
CEO & Director recently sold €98k worth of stock Aug 13
Insufficient new directors Aug 09
Forecast to breakeven in 2025 Aug 09
Paratek Pharmaceuticals, Inc. Announces Modification of Barda Contract to Advance the Development of Nuzyra®? (Omadacycline) for Post-Exposure Prophylaxis (Pep) and Treatment of Pulmonary Anthrax Jul 11
NexPoint Advisors Sends a Letter to Paratek Pharmaceuticals Jun 28
Paratek Pharmaceuticals, Inc. Presents New Data from NUZYRA®? (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023 Jun 13
Gurnet Point Capital Limited and Novo Holdings A/S entered into a definitive agreement to acquire Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) for approximately $130 million. Jun 08
Gurnet Point Capital Limited and Novo Holdings A/S entered into a definitive agreement to acquire Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) for approximately $130 million. Jun 07
Paratek Pharmaceuticals, Inc., Annual General Meeting, Jul 06, 2023 May 27
Paratek Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2023 May 12
First quarter 2023 earnings released: US$0.35 loss per share (vs US$0.34 loss in 1Q 2022) May 10 Mar 18
Full year 2022 earnings released: US$1.17 loss per share (vs US$1.22 loss in FY 2021) Mar 17
Paratek Pharmaceuticals, Inc. Announces Inclusion of NUZYRA(R) (omadacycline) in China's National Reimbursement Drug List Jan 19
Paratek Pharmaceuticals, Inc. Appoints Jeffrey Stein as First Lead Independent Director Dec 21
Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA (omadacycline) under BARDA Project BioShield Dec 20
Insufficient new directors Nov 17
Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in 3Q 2021) Nov 05
Paratek Pharmaceuticals, Inc. Announces First Milestone Towards Creating A U.S. Manufacturing Supply Chain for Nuzyra® (Omadacycline) Under Barda Project Bioshield Contract Nov 01
Paratek Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 26
Forecast breakeven date pushed back to 2024 Aug 09
Second quarter 2022 earnings released: US$0.33 loss per share (vs US$0.20 profit in 2Q 2021) Aug 04
Paratek Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Jul 26
Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from Russell 2000 Dynamic Index Jun 26
Forecast breakeven date pushed back to 2024 May 07
First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.39 loss in 1Q 2021) May 06
Paratek Pharmaceuticals, Inc. Reiterates Guidance for the Year 2022 May 05
Insufficient new directors Apr 29
Paratek Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2022 Apr 23
Forecast breakeven date pushed back to 2023 Mar 15 Paratek Pharmaceuticals, Inc. Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA in A Hollow Fiber System Model Against Pulmonary Mycobacterium Avium Complex Mar 10
Paratek Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 14, 2022 Mar 04
Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.46 loss in 3Q 2020) Nov 09
Paratek Pharmaceuticals Presents New Data for NUZYRA® (omadacycline) at IDWeek 2021 Sep 24
Forecast to breakeven in 2022 Sep 23
Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria Aug 20
Second quarter 2021 earnings released: EPS US$0.21 (vs US$0.53 loss in 2Q 2020) Aug 10
Paratek Pharmaceuticals, Inc. Announces First Barda Project Bioshield Procurement of Nuzyra Jun 30 Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from Russell 3000E Value Index
Forecast breakeven pushed back to 2023 Jun 22
Paratek Pharmaceuticals, Inc. Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) with Nuzyra (Omadacycline) Jun 17
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Jun 02
Forecast breakeven moved forward to 2022 May 20
First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.66 loss in 1Q 2020) May 19
Forecast breakeven moved forward to 2021 May 18
Full year 2020 earnings released: US$2.19 loss per share (vs US$3.93 loss in FY 2019) Mar 31
Full year 2020 earnings released: US$2.19 loss per share (vs US$3.93 loss in FY 2019) Feb 26
Revenue misses expectations Feb 26
Paratek Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: €6.29 Feb 07
New 90-day high: €5.64 Dec 05
Revenue beats expectations Nov 07
Third quarter 2020 earnings released: US$0.46 loss per share Nov 07
Paratek Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 28
New 90-day low - €3.53 Sep 10
First half earnings released Aug 10
New 90-day high - €3.68 Aug 03
Paratek Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Jul 31 Shareholder Returns N4CN DE Pharmaceuticals DE Market 7D 0.4% -2.5% -2.6% 1Y -13.9% -15.6% 6.9%
See full shareholder returns
Return vs Market: N4CN underperformed the German Market which returned 14.4% over the past year.
Price Volatility Is N4CN's price volatile compared to industry and market? N4CN volatility N4CN Average Weekly Movement 5.7% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: N4CN has not had significant price volatility in the past 3 months.
Volatility Over Time: N4CN's weekly volatility has decreased from 15% to 6% over the past year.
About the Company Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.
Show more Paratek Pharmaceuticals, Inc. Fundamentals Summary How do Paratek Pharmaceuticals's earnings and revenue compare to its market cap? N4CN fundamental statistics Market cap €119.98m Earnings (TTM ) -€58.88m Revenue (TTM ) €166.13m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) N4CN income statement (TTM ) Revenue US$177.00m Cost of Revenue US$64.13m Gross Profit US$112.87m Other Expenses US$175.60m Earnings -US$62.73m
Last Reported Earnings
Jun 30, 2023
Earnings per share (EPS) -1.09 Gross Margin 63.77% Net Profit Margin -35.44% Debt/Equity Ratio -128.3%
How did N4CN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/09/22 09:04 End of Day Share Price 2023/09/20 00:00 Earnings 2023/06/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Paratek Pharmaceuticals, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Ulz Baird Jason Matthew Gerberry BofA Global Research Timothy Chiang BTIG
Show 9 more analysts 
